中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

免疫检查点抑制剂所致肝脏不良反应的研究进展

王宇 李钊颖 李爽 刘成海

引用本文:
Citation:

免疫检查点抑制剂所致肝脏不良反应的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.01.039
基金项目: 

上海市宝山区卫生与计划生育委员会重点专科建设 (BSK-2018-A03);

上海市卫生健康委员会科研项目计划 (20214Y0236)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:王宇负责课题设计,资料分析,撰写论文;李钊颖参与收集数据,修改论文;王宇负责拟定写作思路,刘成海、李爽指导撰写文章并最后定稿。
详细信息
    通信作者:

    刘成海,chenghailiu@hotmail.com

Research advances in adverse liver reactions caused by immune checkpoint inhibitors

Research funding: 

Key specialty construction of Shanghai Baoshan District Health and Family Planning Commission (BSK-2018-A03);

Shanghai Municipal Health Commission Research project plan (20214Y0236)

  • 摘要: 免疫检查点抑制剂通过阻断T淋巴细胞负性调控信号以达到增强T淋巴细胞抗肿瘤效应的同时,也可能造成免疫耐受失衡或正常免疫亢进从而导致免疫性肝炎。本文主要通过对免疫检查点抑制剂的治疗机制,导致肝损伤的不良反应机制、危险因素以及发生率等方面进行回顾分析,并且对免疫检查点抑制剂导致肝损伤的治疗方法进行初步归纳。认为免疫检查点抑制剂在促进抗肿瘤免疫的同时,由于作用机制的非肿瘤组织靶点特异性,可能造成非同质化的免疫相关的肝损伤,治疗上以恢复免疫稳态为主。因此,免疫检查点抑制剂应用患者的管理往往需要在治疗窗、毒性和特定损伤治疗之间取得平衡,并开展多学科协作。

     

  • [1] PRIETO LI, BAKER DJ. Cellular senescence and the immune system in cancer[J]. Gerontology, 2019, 65(5): 505-512. DOI: 10.1159/000500683.
    [2] ALARD E, BUTNARIU AB, GRILLO M, et al. Advances in anti-cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets[J]. Cancers (Basel), 2020, 12(7): 1826. DOI: 10.3390/cancers12071826.
    [3] HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.
    [4] WEI SC, DUFFY CR, ALLISON JP. Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8(9): 1069-1086. DOI: 10.1158/2159-8290.CD-18-0367.
    [5] THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.
    [6] NISHIDA N, KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int, 2019, 13(3): 248-252. DOI: 10.1007/s12072-018-9921-7.
    [7] TAN JR, HU CP. Fatal adverse events related to immune checkpoint inhibitors and the management strategies[J]. Chin J Pract Intern Med, 2020, 40(4): 340-344. DOI: 10.19538/j.nk2020040116.

    谭嘉蓉, 胡成平. 免疫检查点抑制剂相关致命性不良反应及管理策略[J]. 中国实用内科杂志, 2020, 40(4): 340-344. DOI: 10.19538/j.nk2020040116.
    [8] LI L, LI G, RAO B, et al. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population[J]. Sci Rep, 2020, 10(1): 15567. DOI: 10.1038/s41598-020-72649-5.
    [9] HAANEN J, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv119-iv142. DOI: 10.1093/annonc/mdx225.
    [10] KITAGATAYA T, SUDA G, NAGASHIMA K, et al. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan[J]. J Gastroenterol Hepatol, 2020, 35(10): 1782-1788. DOI: 10.1111/jgh.15041.
    [11] MIZUNO K, ITO T, ISHIGAMI M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies[J]. J Gastroenterol, 2020, 55(6): 653-661. DOI: 10.1007/s00535-020-01677-9.
    [12] ALESSANDRINO F, TIRUMANI SH, KRAJEWSKI KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: Chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors[J]. Clin Radiol, 2017, 72(7): 521-533. DOI: 10.1016/j.crad.2017.04.003.
    [13] WANG W, LIE P, GUO M, et al. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data[J]. Int J Cancer, 2017, 141(5): 1018-1028. DOI: 10.1002/ijc.30678.
    [14] YAMAMOTO A, YANO Y, UEDA Y, et al. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers[J]. J Cancer Res Clin Oncol, 2021, 147(6): 1747-1756. DOI: 10.1007/s00432-020-03448-8.
    [15] de MARTIN E, MICHOT JM, ROSMORDUC O, et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors[J]. JHEP Rep, 2020, 2(6): 100170. DOI: 10.1016/j.jhepr.2020.100170.
    [16] SAWADA K, HAYASHI H, NAKAJIMA S, et al. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor[J]. J Gastroenterol Hepatol, 2020, 35(6): 1042-1048. DOI: 10.1111/jgh.14889.
    [17] CHOWELL D, MORRIS L, GRIGG CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy[J]. Science, 2018, 359(6375): 582-587. DOI: 10.1126/science.aao4572.
    [18] CHENG AL, HSU C, CHAN SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 307-319. DOI: 10.1016/j.jhep.2019.09.025.
    [19] POSTOW MA, SIDLOW R, HELLMANN MD. Immune-Related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
    [20] FESSAS P, POSSAMAI LA, CLARK J, et al. Immunotoxicity from checkpoint inhibitor therapy: Clinical features and underlying mechanisms[J]. Immunology, 2020, 159(2): 167-177. DOI: 10.1111/imm.13141.
    [21] MALNICK SDH, ABDULLAH A, NEUMAN MG. Checkpoint inhibitors and hepatotoxicity[J]. Biomedicines, 2021, 9(2): 101. DOI: 10.3390/biomedicines9020101.
    [22] LOMBARDI A, MONDELLI MU. Review article: Immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects[J]. Aliment Pharmacol Ther, 2019, 50(8): 872-884. DOI: 10.1111/apt.15449.
    [23] HSU C, MARSHALL JL, HE AR. Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment[J]. Oncologist, 2020, 25(2): 105-111. DOI: 10.1634/theoncologist.2018-0162.
    [24] HAGIWARA S, WATANABE T, KUDO M, et al. Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease[J]. Sci Rep, 2021, 11(1): 9242. DOI: 10.1038/s41598-021-88824-1.
    [25] AFFOLTER T, LLEWELLYN HP, BARTLETT DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice[J]. PLoS One, 2019, 14(5): e0217276. DOI: 10.1371/journal.pone.0217276.
    [26] LOMBARDI A, MONDELLI MU. Review article: Immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects[J]. Aliment Pharmacol Ther, 2019, 50(8): 872-884. DOI: 10.1111/apt.15449.
    [27] NISHIDA N, KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int, 2019, 13(3): 248-252. DOI: 10.1007/s12072-018-9921-7.
    [28] de MARTIN E, MICHOT JM, PAPOUIN B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors[J]. J Hepatol, 2018, 68(6): 1181-1190. DOI: 10.1016/j.jhep.2018.01.033.
    [29] KARAMCHANDANI DM, CHETTY R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: Pathologists' perspective[J]. J Clin Pathol, 2018, 71(8): 665-671. DOI: 10.1136/jclinpath-2018-205143.
    [30] KAWAKAMI H, TANIZAKI J, TANAKA K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer[J]. Invest New Drugs, 2017, 35(4): 529-536. DOI: 10.1007/s10637-017-0453-0.
    [31] ZEN Y, CHEN YY, JENG YM, et al. Immune-related adverse reactions in the hepatobiliary system: Second-generation check-point inhibitors highlight diverse histological changes[J]. Histopathology, 2020, 76(3): 470-480. DOI: 10.1111/his.14000.
    [32] ZHANG QY, CHEN LL, GAO F, et al. Pathological features of immune-mediated hepatitis due to immune checkpoint inhibitors and anti-angiogenesis targeted therapy[J]. Chin J Pathol, 2020, 49(4): 329-335. DOI: 10.3760/cma.j.cn112151-20190720-00403.

    章琼燕, 陈伶俐, 高峰, 等. 免疫检查点抑制剂治疗后肝功能异常的组织病理学分析[J]. 中华病理学杂志, 2020, 49(4): 329-335. DOI: 10.3760/cma.j.cn112151-20190720-00403.
    [33] JOHNCILLA M, MISDRAJI J, PRATT DS, et al. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases[J]. Am J Surg Pathol, 2015, 39(8): 1075-1084. DOI: 10.1097/PAS.0000000000000453.
    [34] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [35] ESFAHANI K, CALABRESE L. Reply to 'Personalized treatment of immune-related adverse events-balance is required'[J]. Nat Rev Clin Oncol, 2020, 17(8): 518. DOI: 10.1038/s41571-020-0401-3.
    [36] Guidelines Working Committee of the Chinese Society of Clinical Oncology. Guidelines for the management of toxicity related to immune checkpoint inhibitors of the Chinese Society of Clinical Oncology (CSCO)[M]. Beijing: People's Medical Publishing House, 2019: 1-116.

    中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2019: 1-116.
    [37] POSTOW MA. Managing immune checkpoint-blocking antibody side effects[J]. Am Soc Clin Oncol Educ Book, 2015 : 76-83. DOI: 10.14694/EdBook_AM.2015.35.76.
    [38] LU JF, PENG Z, ZHU XG, et al. Immune checkpoint inhibitor related hepatotoxicity[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(2): 1-5. DOI: 10.3969/j.issn.1674-7380.2021.02.001.

    鲁俊锋, 彭智, 朱向高, 等. 免疫检查点抑制剂相关肝毒性[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(2): 1-5. DOI: 10.3969/j.issn.1674-7380.2021.02.001.
    [39] NAKANO K, NISHIZAWA M, FUKUDA N, et al. Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis[J]. Oxf Med Case Reports, 2020, 2020(4): omaa027. DOI: 10.1093/omcr/omaa027.
    [40] MCGUIRE HM, SHKLOVSKAYA E, EDWARDS J, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: A case report[J]. Cancer Immunol Immunother, 2018, 67(4): 563-573. DOI: 10.1007/s00262-017-2107-7.
    [41] ZHANG N, LIU XL, XU ZQ, et al. Research progress in relationship between tumor anti-angiogenesis and immunotherapy[J]. J Jilin Univ(Med Edit), 2021, 47(4): 1056-1063. DOI: 10.13481/j.1671-587X.20210434.

    张娜, 刘相良, 徐志强, 等. 肿瘤抗血管生成及其与免疫治疗关系的研究进展[J]. 吉林大学学报(医学版), 2021, 47(4): 1056-1063. DOI: 10.13481/j.1671-587X.20210434.
  • 加载中
计量
  • 文章访问数:  970
  • HTML全文浏览量:  192
  • PDF下载量:  216
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-07
  • 录用日期:  2021-06-28
  • 出版日期:  2022-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回